Viking Therapeutics, Inc.
VKTX
Ранг среди акций
#4539
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Цена акции
$26.41
Рыночная капитализация
$3.36B
Изменение (1 день)
-1.12%
Изменение (1 год)
-19.92%
Страна
US
Торговля Viking Therapeutics, Inc. (VKTX)
Категория
Healthcare
Коэффициент P/B для Viking Therapeutics, Inc. (VKTX)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Viking Therapeutics, Inc., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Viking Therapeutics, Inc. с 2026 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| Недостаточно данных для указанных дат. | ||
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
